These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20371467)

  • 1. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.
    García-Lerma JG; Cong ME; Mitchell J; Youngpairoj AS; Zheng Q; Masciotra S; Martin A; Kuklenyik Z; Holder A; Lipscomb J; Pau CP; Barr JR; Hanson DL; Otten R; Paxton L; Folks TM; Heneine W
    Sci Transl Med; 2010 Jan; 2(14):14ra4. PubMed ID: 20371467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
    Subbarao S; Otten RA; Ramos A; Kim C; Jackson E; Monsour M; Adams DR; Bashirian S; Johnson J; Soriano V; Rendon A; Hudgens MG; Butera S; Janssen R; Paxton L; Greenberg AE; Folks TM
    J Infect Dis; 2006 Oct; 194(7):904-11. PubMed ID: 16960777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
    Radzio J; Aung W; Holder A; Martin A; Sweeney E; Mitchell J; Bachman S; Pau CP; Heneine W; García-Lerma JG
    PLoS One; 2012; 7(12):e50632. PubMed ID: 23226529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
    García-Lerma JG; Otten RA; Qari SH; Jackson E; Cong ME; Masciotra S; Luo W; Kim C; Adams DR; Monsour M; Lipscomb J; Johnson JA; Delinsky D; Schinazi RF; Janssen R; Folks TM; Heneine W
    PLoS Med; 2008 Feb; 5(2):e28. PubMed ID: 18254653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
    Kersh EN; Luo W; Adams DR; Mitchell J; Garcia-Lerma JG; Heneine W; Folks TM; Butera S; Otten RA
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):543-6. PubMed ID: 18370590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
    Van Rompay KK; Schmidt KA; Lawson JR; Singh R; Bischofberger N; Marthas ML
    J Infect Dis; 2002 Nov; 186(10):1508-13. PubMed ID: 12404171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.
    Cong ME; Youngpairoj AS; Zheng Q; Aung W; Mitchell J; Sweeney E; Hanson DL; Hendry RM; Dobard C; Heneine W; García-Lerma JG
    J Virol; 2011 Aug; 85(15):7933-6. PubMed ID: 21632769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
    Smith MS; Foresman L; Lopez GJ; Tsay J; Wodarz D; Lifson JD; Page A; Wang C; Li Z; Adany I; Buch S; Bischofberger N; Narayan O
    Virology; 2000 Nov; 277(2):306-15. PubMed ID: 11080478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention.
    Subbarao S; Ramos A; Kim C; Adams D; Monsour M; Butera S; Folks T; Otten RA
    J Med Primatol; 2007 Aug; 36(4-5):238-43. PubMed ID: 17669212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.
    Ross TM; Pereira LE; Luckay A; McNicholl JM; García-Lerma JG; Heneine W; Eugene HS; Pierce-Paul BR; Zhang J; Hendry RM; Smith JM
    AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1072-81. PubMed ID: 24914761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
    PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
    Clercq ED
    Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
    Cong ME; Mitchell J; Sweeney E; Bachman S; Hanson DL; Heneine W; García-Lerma JG
    J Infect Dis; 2013 Aug; 208(3):463-7. PubMed ID: 23633402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.
    Veazey RS; Springer MS; Marx PA; Dufour J; Klasse PJ; Moore JP
    Nat Med; 2005 Dec; 11(12):1293-4. PubMed ID: 16273102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates.
    Kim CN; Adams DR; Bashirian S; Butera S; Folks TM; Otten RA
    J Med Primatol; 2006 Aug; 35(4-5):210-6. PubMed ID: 16872284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
    De Clercq E
    Med Res Rev; 2012 Jul; 32(4):765-85. PubMed ID: 22581627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
    Van Rompay KK; McChesney MB; Aguirre NL; Schmidt KA; Bischofberger N; Marthas ML
    J Infect Dis; 2001 Aug; 184(4):429-38. PubMed ID: 11471100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic preexposure prophylaxis for human immunodeficiency virus infection.
    Romanelli F; Murphy B
    Pharmacotherapy; 2010 Oct; 30(10):1021-30. PubMed ID: 20874040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis.
    Kersh EN; Adams DR; Youngpairoj AS; Luo W; Zheng Q; Cong ME; Aung W; Mitchell J; Otten R; Hendry RM; Heneine W; McNicholl J; Garcia-Lerma JG
    PLoS One; 2011 Apr; 6(4):e19295. PubMed ID: 21541293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.